Atypical psychotropic medications and their adverse effects: A review for the African-American primary care physician

Journal of the National Medical Association

Volumn 95, Issue 2, 2003, Pages 137-144

  Bailey, Rahn Kennedy ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NIZATIDINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TOPIRAMATE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIRENZEPINE; THIAZOLE DERIVATIVE;

APPETITE DISORDER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GENERAL PRACTITIONER; GENERALIZED ANXIETY DISORDER; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LONG QT SYNDROME; MENTAL DISEASE; NEGRO; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN; ADULT; AFRICAN AMERICAN; AGED; BONE MARROW DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; METHODOLOGY; PRIMARY HEALTH CARE;

ADULT; AFRICAN AMERICANS; AGED; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; BENZODIAZEPINES; BONE MARROW DISEASES; CHILD; DIBENZOTHIAZEPINES; ENDOCRINE SYSTEM DISEASES; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PIPERAZINES; PIRENZEPINE; PRIMARY HEALTH CARE; RISPERIDONE; THIAZOLES;

EID: 0037977005     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Tohen MF, Sanger TM, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. American Journal of Psychiatry. 1999; 156: 702-9.
2. Ghaemi SN, Sachs GS, Baldassano CF, et al: Acute treatment of Bipolar Disorder with adjunctive risperidone in outpatients. Canadian Journal of Psychiatry. 1997; 42: 196-9.
3. Shelton RC, et al. The effectiveness of Olanzapine augmentation to fluoxetine for the treatment of resistant depression. American Journal of Psychiatry. 2001; 158: 131-134.
4. Casey DE. Clozapine. Neuroleptic induced EPS and tardive dyskinesia. Psychopharmacology. 1989; 99: S47-S53.
5. Pfizer Inc. Geodon (Ziprasidone) package insert. New York, New York. 2001.
6. Atkin K, Kendall F, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. British Journal of Psychiatry. 1996; 169: 483-8.
7. Kane J, Honigfeld G, et al. Clozapine for the Treatment Resistant Schizophrenic: A Double Blind Comparison with Chlorpromazine. Archives of General Psychiatry. 1988; 45: 789-796.
8. Physicians' Desk Reference, Montvale, NJ. Medical Economics Co., 2002.
9. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry. 1994, 55 (Suppl B): 133-136.
10. Perry PJ, Miller DD, Arndt SV et al. Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics. American Journal of Psychiatry. 1991; 148: 231-235.
11. Glazer WM. Extrapyramidal side effects, tardive dyskinesia and the concept of atypicality. Journal of Clinical Psychiatry. 2000; 61 (Suppl 3): 16-21.
12. Mokdad AH, Bowman BA, et al: The continuing epidemics of obesity and diabetes in the US. Journal of American Medical Association. 2001; 286: 1195-1200.
13. Mukhergee S, Decina P et al. Diabetes Mellitus in schizophrenic patient. Comprehensive Psychiatry. 1996; 37: 68-73.
14. Lorenz WF, Sugar tolerance in dementia praecox and other mental disorders. Archives of Neurology and Psychiatry. 1922; 8: 184-196.
15. Charatan FBE, Bartlett NG. The effect of chlorpromazine ("Largactil") on glucose intolerance. Journal of Mental Science. 1955; 101: 351-353.
16. McIntyre RS, McCann SM, et al: Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Canadian Journal of Psychiatry. 2001; 46: 273-281.
17. Wirshing DA, Wirshing WC, et al: Novel antipsychotics. comparison of weight gain liabilities. Journal of Clinical Psychiatry. 1999; 60: 358-363.
18. Allison DB, Mentore JL, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 1999; 156: 1686-1696.
19. O'Keefe C, Noordsy D, et al. Reversal of Weight Gain Associated with antipsychotic treatment. Presented at 154th APA Annual Meeting. May 5-10, 2001, New Orleans, LA.
20. Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Clinical Neuropharmacology. 1988; 11 (suppl 1): S, 194-206.
21. Heisler LK, Chu HM, and Tecott LH: Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Annals NY Academy of Sciences, 1998; 861: 74-78.
22. Glick ID, et al. Insulin Resistance in Olanzepine and Ziprasidone treated patients. Results of a double blind controlled six-week trial. Presented at the APA Meeting. New Orleans, LA, 2000.
23. Wirshing DA. Adverse Effects of Atypical Antipsychotics. Journal of Clinical Psychiatry. 2001; 62 (suppl 21): 7-10.
24. Littrell KH, Petty R, et al: Educational Intervention for the Management of antipsychotic related weight gain. Presented at 154th APA Annual Meeting May 5-10, 2001. New Orleans, LA.
25. Nguyen CT, Ortiz T, et al. Nutritional Education in Minimizing Weight Gain associated with antipsychotic therapy. Presented at 154th APA Annual Meeting May 5-10, 2001. New Orleans, LA.
26. Hummer M, Kenunler G, Kurz M et al. Weight gain induced by clozapine. European neuropsychopharmacology, 1995; 5: 437-440.
27. Kinon, BJ, Basson BR, et al. Long-term Olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry. 2001; 62: 92-100.
28. Basson BR, Kinon BJ, Taylor CC et al. Factors influencing weight change in patients with schizophrenia treated with olanzapine versus haloperidol of fisperidone. Presented at the 51st Institute on Psychiatric Services; 1999, New Orleans, LA.
29. Floris M, Deberdt W, et al. Effect of Amantadine on Weight gain during Olanzapine treatment. European Neuropsychopharmacology. 2001; 11: 181-182.
30. Breier A, Tanaka Y, et al: Nizatidine for the Prevention of Olanzapine-Associated weight gain in schizophrenia and related disorders - A Randomized Controlled Double Blind Study. Presented at 41st New Clinical Drug Evaluation Unit (NCDEU); May 28-31, 2001. Phoenix, AR.
31. Allison DB, Fontaine KR, Heo M et al. The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry. 1999; 60: 215-220.
32. Melkersson KI, Hulting AL, Brismar KE: Elevated levels of insulin, leptin and blood lipids in Olanzapine-treated patients with schizophrenia or related psychosis. Journal of Clinical Psychiatry. 2000; 61: 742-749.
33. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am J of Psychiatry 2000; 157: 975-981.
34. Rockwell WJK, Ellinwood EH Jr., Trader DW. Psychotropic drugs promoting weight gain: health risks and treatment implications. Southern Medical Journal. 1983; 76: 1407-1412.
35. Rubin RJ, Altman WM, et al: Health Care Expenditures for people with diabetes mellitus, 1992. Journal of Clinical Endocrinology and Metabolism. 1994; 78: 809 A-F.
36. Mckee HA, D'Arcy PF, Wilson PJ: Diabetes and schizophrenia. Journal of Clinical and Hospital Pharmacy. 1986; 11: 297-9.
37. Harris MI, Flegal KM, et al: Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-24.
38. Dixon L, Weiden P, Delahanty J et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin. 2000, 26: 903-912.
39. Kraemer HC, Stice E, Kazdin A, et al. How do risk factors work together? Mediators, moderators and independent overlapping and proxy risk factors. American Journal of Psychiatry. 2001, 158: 848-856.
40. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophrenia Research. 1999; 35 Suppl: S67-73.
41. Kapur S, Zipursky RB, et al: Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double blind PET study of first-episode schizophrenia. American Journal of Psychiatry. 2000; 157: 514-20.
42. Conley RR: Risperidone side effects. J Clin Psychiatry. 2000; 61 suppl 8: 20-3; discussion 24-5.
43. Pfizer Inc. Study report on Ziprasidone Clinical Pharmacology Protocol, Rockville, MD: FDA Center for Drug Evaluation and Research Division of Cardio Renal Drug Products Consultation. June 14, 2000.
44. Ahnve S. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. American Heart Journal. 1985; 109: 568-574.
45. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. Journal of Clinical Psychiatry. 1999; 60 (Suppl 3): 3-7.
46. Krakowski MI, Kurz M, Czobor P et al. Long-term high dose neuroleptic treatment: who gets it and why? Hospital Community Psychiatry. 1993; 44: 640-644.
47. Casey DE, Keepers GA: Neuroleptic side effects, acute extrapyramidal symptoms and tardive dyskinesia. Psychopharmacology. Series 1988, 5: 74-93.
48. Casey DE. Hirsch S, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995: 546-565.
49. Kapur S, Seeman P. Does Fast Dissociation from the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics? A New Hypothesis. American Journal of Psychiatry. 2001; 158: 3. 360-69.
50. Seeman P and Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Molecular Psychiatry, 1998; 3: 123-134.
51. Kapur S, Zipursky RB, et al: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of Clozapine, Risperidone and Olanzapine in schizophrenia. American Journal of Psychiatry. 1999; 156: 286-93.
52. Chakos M, Lieberman J, Hoffman E et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry. 2001; 158: 518-526.
53. Stahl S. Fiscal pharmacology of the novel antipsychotics: getting the biggest bang out of the bucks. Orange County Psychiatric Society Meeting (sponsored by AstraZeneca, Janssen, Eli Lilly and Pfizer) January 2002, Dana Point, CA.
54. Kinon BJ, Stauffer V, et al. Poster presented at APA 53rd Annual Institute of Psychiatric Services, October 2001, Orlando, FL.
55. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry. 1999; 60: 107-115.
56. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with Olanzapine: three case reports. Annals of Clinical Psychiatry. 1999; 11: 233-6.
57. Maguire GA, Riley GD, et al: Risperidone for the treatment of stuttering. Journal of Clinical Psychopharmacology. 2000; 20: 479-82.
58. Littrell KH, Petty RG et al: Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse and Treatment. 2001; 21: 217-21.